Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
boston blog main
deals
9
×
life sciences
national blog main
san francisco blog main
9
×
boston top stories
national top stories
clinical trials
san francisco top stories
boston
startups
fda
investing
ipo
new york blog main
new york top stories
abbvie
akouos
allergan
alnylam pharmaceuticals
cancer
crispr
editas medicine
eli lilly
genentech
hepatitis b
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco
sanofi
sickle cell disease
third rock ventures
vc
venture capital
What
medicines
9
×
drug
biotech
deal
ipo
new
research
alliance
cancer
developing
fda
pact
plans
startup
therapeutics
abandoning
abbvie
acquisitions
adds
affects
ago
aiming
aims
ambys
americans
announced
approach
approval
approved
areas
baggage
based
big
bio
biosciences
bio’s
blueprint
brii
called
candidate
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?